Amiodarone is an antiarrhythmic agent known to cause prolongation of action potential duration which is re• flected in the electrocardiogram as a prolongation of the QT interval. Prolongation of the QT interval in patients dying suddenly was compared with that in patients who remained alive to determine whether a difference existed between these two groups. The electrocardiogram and amiodarone levels were evaluated in 33 patients who presented with cardiac arrest and symptomatic ventric• ular tachycardia in whom no other antiarrhythmic agent was found effective in preventing induction of ventric• ular tachycardia during electrophysiologic studies. There were 30 men and 3 women (mean age 62 ± 10 years). Twenty-three are alive after a mean follow-up period of 12 ± 7 months. Ten died: six suddenly, three of non• cardiac causes and one of congestive heart failure.
QT Prolongation and the Antiarrhythmic Efficacy of Amiodarone
Amiodarone is an antiarrhythmic agent known to cause prolongation of action potential duration which is re• flected in the electrocardiogram as a prolongation of the QT interval. Prolongation of the QT interval in patients dying suddenly was compared with that in patients who remained alive to determine whether a difference existed between these two groups. The electrocardiogram and amiodarone levels were evaluated in 33 patients who presented with cardiac arrest and symptomatic ventric• ular tachycardia in whom no other antiarrhythmic agent was found effective in preventing induction of ventric• ular tachycardia during electrophysiologic studies. There were 30 men and 3 women (mean age 62 ± 10 years). Twenty-three are alive after a mean follow-up period of 12 ± 7 months. Ten died: six suddenly, three of non• cardiac causes and one of congestive heart failure.
Prolongation of the QT interval has been considered a proar• rhythmic phenomenon that increases myocardial vulner• ability (I). Quinidine-induced prolongation of the QT in• terval (2, 3) and the hereditary long QT syndrome (4) are often cited as examples of the association of QT prolon• gation and a proarrhythmic effect. Amiodarone is an an• tiarrhythmic agent known to cause prolongation of action potential duration possibly mediated by changes in voltage• dependent refractoriness (5) (6) (7) . Unlike quinidine, prolon• gation of the QT interval with amiodarone is voltage de• pendent, not time dependent and changes in refractoriness are homogeneous, thus avoiding the possibility of a phar• macologically induced reentrant mechanism (7) . Prolon• gation of action potential duration has been proposed as a mechanism for the antiarrhythmic effect of amiodarone be• cause this agent acts predominantly on repolarization and Using a two-way analysis of variance, the percent change in QT, QTc, JT and JTc intervals before and after amiodarone therapy was analyzed. Marked pro• longation in the QT interval was present in patients who remained alive with amiodarone therapy. A significant difference in percent QT prolongation was seen between the latter patients and those who died suddenly (p < 0.005). No difference was observed in the percent change in QRS interval between the two groups. The levels of amiodarone (2.5 versus 3.2 p.g/ml) and its metabolite (desethylamiodarone) were not significantly different be• tween the living patients and those who died suddenly. These findings suggest that a prolongation of the QT interval may be a marker for the therapeutic antiar• rhythmic effect of amiodarone.
(J Am Coli CardioI1986;7:142-7)
has minor effects on cardiac depolarization. During long• term administration amiodarone has been shown to cause prolongation of the QT interval on the surface electrocar• diogram, a finding indicative of the time course of ventric• ular repolarization (8) . Whether the QT prolongation seen with amiodarone is a marker of drug effect has not been established.
We specifically compared the QT interval with other electrocardiographic intervals in patients treated with amio• darone to determine whether QT prolongation was a marker of the antiarrhythmic action of amiodarone. If a difference existed in the degree of QT prolongation in patients who remained alive and patients who died suddenly, this would support the thesis that amiodarone acts by prolonging re• polarization. If this thesis is correct, QT prolongation could be used as a marker for the therapeutic efficacy of amiodarone.
Methods
Patients. Electrocardiographic data were obtained in 33 patients who started amiodarone therapy because ventricular tachycardia remained inducible at programmed electrical stimulation testing after the administration of conventional 0735-10971861$3.50 and investigational agents. These patients were initially re• ferred for electrophysiologic testing because of recurrent cardiac arrest or symptomatic ventricular tachycardia. No patient was excluded from analysis on the basis of a low ejection fraction, New York Heart Association class IV congestive heart failure or baseline electrocardiographic ab• normalities. All patients had available a 12 lead electro• cardiogram before starting amiodarone therapy and match• ing electrocardiogram and amiodarone levels at the time of the electrocardiographic analysis. All patients underwent electrophysiologic studies without any antiarrhythmic agents and subsequent serial drug testing with a minimum of four drugs tested before their discharge on amiodarone. After their hospitalization, patients were followed up at 1. 3 and 6 month intervals with serial electrocardiograms and serum amiodarone levels determined for a perspective analysis of indicators of clinical outcome.
Programmed stimulation protocol. After informed consent was obtained, electrophysiologic studies were per• formed with patients in a fasting non sedated state. Pro• grammed electrical stimulation was performed using a hex• apolar pacing catheter introduced through the right internal jugular vein to the apex of the right ventricle. In patients in whom ventricular tachycardia could not be induced from the right ventricular apex, the catheter was repositioned to the right ventricular outflow tract. A digital stimulator (Bloom Associates) was used to deliver square wave electrical im• pulses 2 ms in duration with amplitude set at least twice diastolic threshold. The right ventricle was driven with a pacing train of 6 beats at a cycle length of 500 ms with an intertrain interval of 8 seconds.
Serial drug testing. All patients were tested at pro• grammed electrical stimulation with conventional antiar• rhythmic agents. A period of five half-lives of the drug was allowed before the administration of the next agent. The drugs were administered as follows: lidocaine. 1 mg/kg body weight bolus followed by a 2 mg/min infusion, procain• amide, 1.000 to 1.500 mg intravenously at a rate of 100 mg every 5 minutes; quinidine, 800 mg intravenously at a rate of 80 mg every 5 to 10 minutes; disopyramide. 150 to 200 mg orally every 6 hours; tocainide. 400 to 600 mg orally every 8 hours; lorcainide, 100 to 200 mg intrave• nously at a rate of 10 mg every 5 minutes: flecainide, 2 mg/kg intravenously administered in three divided doses over 15 minutes; cibenzoline, 1 to 2 mg/kg intravenously over 20 minutes; N-acetylprocainamide. 18 mg/kg as a con• stant infusion over 20 minutes; d-sotalol. 1 to 1.75 mg/kg continuous infusion over 10 minutes; bethanidine. 5 to 10 mg/kg at a rate of 80 mg every 5 minutes; pirmenol, 1.1 mg/kg bolus followed by a 40 j.tg/kg per min infusion.
Electrocardiographic analysis. Twelve lead electro• cardiograms before and after amiodarone therapy were re• viewed by two observers. one of whom did not know the clinical status of the patients. Both observers had initially TORRES ET AL.
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QT PROLONGATION AND AMIODARONE established common guidelines for measurement. The QT interval was measured using the limb lead tracings; the longest measured QT interval in any of the three leads was recorded. Patients with atrial fibrillation were excluded be• cause of the difficulty in measuring QT intervals accurately in this group of patients. The QT interval was also corrected for rate using Bazett's formula. QTc = QT/R + R.
Amiodarone levels. Serum levels of amiodarone and its metabolite desethylamiodarone were measured using high pressure liquid chromatography sensitive to a concentration of 0.5 j.tg/ml.
Statistical analysis. The mean or percent change from the mean ± SD is reported. Difference between means was determined using Student's t test (one-tailed) and a two• way analysis of variance (ANOV A) when appropriate.
Results
Patient characteristics (Table 1) . Thirty-three patients (30 men and 3 women, mean age 62 ± 10 years) were studied. Of these, 25 had arteriosclerotic heart disease (19 had documented myocardial infarction-16 anterior wall, 2 inferior wall and 1 subendocardial-and 6 had coronary artery disease documented by coronary angiography without myocardial infarction); 1 had hypertensive cardiomyopathy; I had mitral valve prolapse; 2 had cardiomyopathy (diabetic and alcoholic) and 1 patient had Lown-Ganong-Levine syn• drome with supraventricular and recurrent ventricular tachy- cardia. Three patients had no evidence of heart disease as judged by clinical assessment. chest X-ray film, electro• cardiogram and echocardiogram. Fourteen patients pre• sented with out-of-hospital cardiac arrest, 11 had recurrent symptomatic ventricular tachycardia and 8 presented with asymptomatic ventricular tachycardia (4 with sustained and 4 with nonsustained tachycardia). These patients had been treated with an average of two antiarrhythmic drugs with no success before electrophysiologic studies. The mean left ventricular ejection fraction for all patients was 28 ± 6%.
Drug therapy. After treatment with at least four drugs failed at electrophysiologic testing, 26 patients were dis• charged receiving amiodarone as the only antiarrhythmic therapy. In an additional seven patients, an effective drug was found during electrophysiologic testing but they had recurrence of ventricular tachycardia, considered a break• through on therapy, and subsequently were given amioda• rone as the only antiarrhythmic therapy. Amiodarone was administered orally, 1,200 mg daily for a week, followed by an additional week of 800 mg daily and then oral dosing between 400 and 600 mg daily with the dose determined by the serum amiodarone concentration with a target con• centration of 2 jLg/ml. Drug efficacy (Table 2) . Twenty-three patients remain alive after a mean follow-up period of 12 ± 7 months (range 3 to 31). Ten patients died; in six the death can be classified as sudden cardiac death, three died of noncardiac causes (peritonitis, metastatic colon carcinoma and pulmonary fi• brosis) and one died of progressive congestive heart failure. Of the six patients who died suddenly, the mean time from the onset of amiodarone therapy to the time of death was 5 ± 1 months (range 1 to 10). Four of the six patients pre• sented initially with cardiac arrest, one with symptomatic ventricular tachycardia and one with asymptomatic ventric- ular tachycardia. Mean radionuclide ventricular ejection fraction for these patients was 29 ± 0.3%. In the four patients dying of noncardiac causes, the times of death after the onset of amiodarone therapy were 1,3.9 and 29 months.
The patient who died from progressive congestive heart failure died 4 months after starting treatment with amio• darone. This patient initially presented with cardiac arrest and had no recurrence of his arrhythmias while receiving amiodarone ( Table 2 ). The levels of amiodarone and its metabolite desethylamiodarone were not significantly dif• ferent between the living patients and those who died sud• denly; amiodarone levels were 2.5 and 3.2 jLg/ml. respec• tively, desethylamiodarone levels are 2.1 and 1.8 jLg/ml, respectively. Serum electrolytes (K +, Na + +, Ca + + and Mg + +) were determined at each patient visit and did not significantly differ among the groups. Electrocardiographic data ( Table 3 ). The heart rate and PR, QRS, QT, QTc, JT and JTc intervals were analyzed before and after amiodarone therapy. These intervals and the percent change from baseline were compared in patients who remained alive and those who died while receiving therapy (Fig. I) . There was no significant difference in the heart rate between the two groups. A slight decrease in heart rate (from 73 to 69 beats/min) was seen for the study group as a whole during amiodarone therapy, but this decrease was not statistically significant. A significant prolongation in PR interval was seen during amiodarone therapy from a mean of 166 ± 32 to 199 ± 34 ms (p < 0.005). However, no significant differences were observed in the absolute or percent change in PR interval or QRS duration between those living and those dying suddenly. Two-way analysis of variance and logistic regression revealed a prolongation in the percent change in QT and JT intervals after amio• darone administration in the patients who remained alive with amiodarone therapy contrasted with those dying sud• denly while receiving the drug; for those alive the percent QT prolongation was 13 ± 3 versus 4 ± 11 for those dying suddenly, a significant difference (p < 0.(05). If the percent change in QT interval of those dying suddenly (4 ± 11) is compared with the QT interval of those alive (10 ± 11) having received the same dose of amiodarone over the same period, those patients who are alive have a significantly prolonged QT interval compared with those who died (p < 0.005).
Holter monitor data. Five of the six patients dying suddenly had ambulatory electrocardiographic (Holter) monitoring before and after amiodarone therapy (3 to 6 weeks after commencing therapy). Of those patients still living, 18 were monitored before and after therapy (3 to 6 weeks after commencing therapy). In the group dying sud• denly the mean ventricular premature complex frequency was 680 ± 79/h and after amiodarone it decreased to 35 ± 7/h. a 95% reduction. In the group surviving, the mean ventricular premature complex frequency before therapy was 963 ± 172th on average and was decreased to 21 ± 19th, a 96% reduction, There was no difference in the percent reduction in premature ventricular complexes between the two groups. Ventricular tachycardia events were decreased from 163 ± 128 to 8 ± 10 in those dying suddenly as contrasted with 137 ± 69 to 0.7 ± 16 in those still living. The percent decrease in ventricular tachycardia events be• tween the two groups did not differ significantly. Adverse effects. Amiodarone has been well tolerated in this group of patients. The major side effects have been gastrointestinal, primarily nausea and constipation. Eleva• tion of serum liver enzymes (glutamic oxaloacetic trans• aminase, glutamic pyruvic transaminase and alkaline phos• phatase) to twice their normal values has been seen without any serious sequelae. In this series one patient died of pul• monary fibrosis possibly attributable to amiodarone; how• ever, the lung biopsy findings were not consistent with the Months of Follow -up changes typically reported for amiodarone-induced pul• monary fibrosis (9,10).
Discussion
Amiodarone and the QT interval. Measurement of the QT interval and its significance have been the subject of controversy. To date, the significance of QT prolongation remains unanswered (11) . The QT interval is still used as a reflector of repolarization despite its limitations in mea• surement. inherent variability, varying T wave configuration and dependence of the QT interval on heart rate (12, 13). Measurement of the QT interval encompasses a composite of many cellular action potentials, and thus it is not an absolute measure of action potential duration (14) . Given these limitations, our study sought to determine whether prolongation of the QT interval had any significance in guiding therapy or predicting survival of patients treated with amiodarone. In this group of patients a significant prolongation in QT interval was seen in the patients who survived. This prolongation clearly indicates that the effect of amiodarone on QT prolongation represents an antiar• rhythmic effect, and those that manifest this prolongation seem to do better. This is in contrast with QT prolongation due to heterogeneity of refractoriness due to myocardial infarction or drugs such as quinidine that are associated with an increased mortality (15) (16) (17) .
Analysis of Holter monitoring results shows no difference in ventricular premature complex or ventricular tachycardia event reduction between the group surviving and the group dying suddenly while taking amiodarone. Both groups show a significant decrease in frequency and complexity of ven• tricular ectopic complexes. Amiodarone is usually effective in suppressing ectopic activity and this suppression occurs in those dying from a suspected arrhythmic event as readily as in those surviving.
QT prolongation and antiarrhythmic action. The pos• sible mechanism for the differences in clinical outcome in patients with a similar prolongation in QT interval has been postulated to be different effects on dispersion of refrac-OT PROLONGATION AND AMIODARONE toriness and action potential duration. Studies have shown that dispersion of refractoriness and increased action poten• tial duration decrease ventricular fibrillation threshold and are arrhythmogenic (18, 19) . Antiarrhythmic agents such as bretylium and procainamide have been shown to decrease dispersion of refractoriness in ischemic canine tissues (20.21) , suggesting that decreasing dispersion of refractoriness is an antiarrhythmic effect. A number of investigational antiar• rhythmic agents such as N-acetylprocainamide and sotalol have been shown to be effective in suppressing atrial and ventricular arrhythmias (22, 23) . These agents cause pro• longation of the QT interval on the surface electrocardio• gram and prolongation of refractoriness without effects on phase 0 of the action potential (24, 25) . Amiodarone causes a prolongation of the action potential duration, voltage• dependent refractoriness and a resultant homogeneous pro• longation in myocardial refractoriness (5) (6) (7) . This uniform prolongation makes the requisite fractionation of myocardial or His-Purkinje recovery time less likely and thus prevents the development of a reentrant tachycardia (7) .
One possibility that could explain our findings is that patients who died suddenly died earlier in the treatment period than patients who are alive and therefore these pa• tients did not live long enough to have amiodarone-induced QT prolongation. Patients who remained alive receiving amiodarone had significant QT prolongation at a mean of 5 ± 2 months into therapy. This was the same time to death seen in the sudden death group who had no significant QT prolongation. The clinical arrhythmia presentation was sim• ilar between those dying suddenly and the group showing QT prolongation and an improved survival. Thus, QT pro• longation acts as a marker for the antiarrhythmic effect of amiodarone.
Amiodarone levels and clinical effects. We found no significant difference in serum amiodarone concentration between those alive and those dying suddenly. It appears that amiodarone levels, although helpful in avoiding drug toxicity (26), may not be as helpful in assessing efficacy. Other methods such as analyzing myocardial (27) or red cell (28) amiodarone levels have been suggested to correlate better than serum levels with the efficacy of amiodarone because these measurements represent the tissue concentra• tion of amiodarone that is exerting the pharmacologic effect. Several studies have suggested that myocardial levels cor• relate with electrophysiologic effect (29) and that length• ening of the QTc interval strongly correlates with antiar• rhythmic efficacy (30) and plasma (31) and myocardial (32) levels. It has been suggested by Debbas et al. (32) that lengthening of the QTc interval may be used clinically to estimate the myocardial concentration of amiodarone.
In addition, the changes in QTc interval lengthening and shortening during therapy and withdrawal of amiodarone parallel the changes seen in the reverse triiodothyronine (T 3) level curves during therapy and withdrawal of amiodarone JACC Vol 7. No I Januaf) 1986 142-7 as well (33) . The levels of reverse T3 have been reported to correlate well with the antiarrhythmic efficacy of amio• darone and its toxicity (34) . The parallel relation of these curves therefore highlights the clinical importance of the QT interval in guiding amiodarone therapy. Because other factors, such as drugs. stress and concurrent illness (35) (36) (37) , affect the levels of reverse T 3, the role of this measurement in relation to dosage and survival remains to be clearly defined.
Guidelines for amiodarone therapy. The results of programmed electrical stimulation in predicting the efficacy of long-term amiodarone therapy also remain controversial. Results from different centers have yielded conflicting re• ports (38) (39) (40) (41) (42) . The work of McGovem and Ruskin (41) and recently the work of Horowitz et al. (42) provide some encouraging guidelines suggesting that patients whose ar• rhythmia is not inducible with amiodarone administration have a good outcome, without recurrence of arrhythmia. Patients whose arrhythmia remains inducible with amio• darone tend to have a worse prognosis and additional forms of therapy are recommended. The findings of our study suggest that QT prolongation during amiodarone therapy is a marker of a desirable drug effect. Clearly, QT prolongation is the easiest marker to follow up on repeat patient visits. Furthermore, our study shows that although QT interval prolongation separates those responding to amiodarone ther• apy from those dying suddenly, amiodarone serum levels were not significantly different between the two groups. Thus, QT prolongation seems the most useful predictor of amiodarone success. These studies suggest that the initial loading dose of amiodarone should be continued until sig• nificant prolongation in QT interval (10 to 15%) is noted and further adjustments are made to maintain this percent QT prolongation. Clearly the observations are based on a small number of patients and our recommendation can be considered as only an initial guideline for therapy.
